Related Experiment Videos
Analysis of CD10+ hairy cell leukemia
Tammy M Jasionowski1, Leah Hartung, Jay H Greenwood
1Department of Pathology, University of Utah, Salt Lake City, UT, USA.
American Journal of Clinical Pathology
|August 23, 2003
Summary
Approximately 10% of Hairy Cell Leukemia (HCL) cases can aberrantly express CD10. This CD10 expression does not appear to alter the typical morphology or clinical presentation of HCL.
Area of Science:
- Hematology
- Immunophenotyping
- Oncology
Background:
- Hairy cell leukemia (HCL) is a rare B-cell malignancy.
- CD10 expression in HCL has been inconsistently reported, with unclear clinical significance.
Purpose of the Study:
- To evaluate the frequency and characteristics of CD10 expression in HCL.
- To determine if CD10 positivity impacts clinical or morphological features of HCL.
Main Methods:
- Retrospective analysis of 97 HCL cases diagnosed over a 2-year period.
- Flow cytometry and immunohistochemical analysis for CD10 expression.
- Review of clinical, morphological, and treatment response data.
Main Results:
- Ten out of 97 (approximately 10%) HCL cases expressed CD10.
- CD10 expression was detectable by flow cytometry and immunohistochemistry.
- CD10+ HCL cases were morphologically and clinically similar to CD10- HCL cases.
- All cases were negative for bcl-6.
Conclusions:
- Aberrant CD10 expression occurs in about 10% of typical HCL cases.
- CD10 positivity does not significantly alter the clinical or morphological phenotype of HCL.
- Recognizing CD10 expression in HCL is crucial for accurate diagnosis, especially with challenging cases.